Plasmodium falciparum clearance is rapid and pitting independent in immune malian children treated with artesunate for malaria

Journal of Infectious Diseases

Volumn 211, Issue 2, 2015, Pages 290-297

  Ndour, Papa Alioune ^a,b   Lopera Mesa, Tatiana M ^c   Diakité, Seidina A S ^d   Chiang, Serena ^c   Mouri, Oussama ^b   Roussel, Camille ^a   Jauréguiberry, Stéphane ^b   Biligui, Sylvestre ^a,b   Kendjo, Eric ^a,b   Claessens, Antoine ^e   Ciceron, Liliane ^a,b   Mazier, Dominique ^a,b   Thellier, Marc ^a,b   Diakité, Mahamadou ^d   Fairhurst, Rick M ^c   Buffet, Pierre A ^a,b  

^a France   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF BAMAKO   (Mali)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

acquired immunity; artemisinin; malaria; parasite clearance; pitting; Plasmodium falciparum; spleen

Indexed keywords

AMODIAQUINE; ARTESUNATE; IMMUNOGLOBULIN G; QUININE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ADAPTIVE IMMUNITY; ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CELL TRANSFORMATION; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHROCYTE DISORDER; FRENCHMAN; HOST PARASITE INTERACTION; HUMAN; HUMAN CELL; IMMUNITY; IN VITRO STUDY; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALIAN; MICROBIAL KINETICS; PARASITE CLEARANCE; PARASITE LOAD; PITTING; SPLEEN FUNCTION; TREATMENT DURATION; ADULT; COHORT ANALYSIS; DRUG EFFECTS; FEMALE; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MALARIA, FALCIPARUM; MALE; MALI; PARASITEMIA; PARASITOLOGY; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; MALARIA, FALCIPARUM; MALE; MALI; PARASITE LOAD; PARASITEMIA; PLASMODIUM FALCIPARUM; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84922496747     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu427     Document Type: Article

References (31)

1. WHO. The treatment of malaria. 2nd ed. Geneva, Switzerland: WHO, 2010.
2. White NJ. The parasite clearance curve. Malar J 2011; 10:278.
3. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366:717-25.
4. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376: 1647-57.
5. Angus BJ, Chotivanich K, Udomsangpetch R, White NJ. In vivo removal of malaria parasites from red blood cells without their destruction in acute falciparum malaria. Blood 1997; 90:2037-40.
6. Chotivanich K, Udomsangpetch R, Dondorp A, et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis 2000; 182:629-33.
7. Newton PN, Chotivanich K, ChierakulW, et al. A comparison of the in vivo kinetics of Plasmodium falciparum ring-infected erythrocyte surface antigen-positive and -negative erythrocytes. Blood 2001; 98:450-7.
8. Schnitzer B, Sodeman T, Mead ML, Contacos PG. Pitting function of the spleen in malaria: ultrastructural observations. Science 1972; 177:175-7.
9. Buffet PA, Milon G, Brousse V, et al. Ex vivo perfusion of human spleens maintains clearing and processing functions. Blood 2006; 107:3745-52.
10. Rogers ZR, Wang WC, Luo Z, et al. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood 2011; 117:2614-7.
11. Buffet PA, Safeukui I, Deplaine G, et al. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 2011; 117:381-92.
12. Deplaine G, Safeukui I, Jeddi F, et al. The sensing of poorly deformable red blood cells by the human spleen can be mimicked in vitro. Blood 2011; 117:e88-95.
13. Chotivanich K, Udomsangpetch R, McGready R, et al. Central role of the spleen in malaria parasite clearance. J Infect Dis 2002; 185:1538-41.
14. Berzins K. Pf155/RESA is not a surface antigen of Plasmodium falciparum-infected erythrocytes. Parasitol Today 1991; 7:193-4.
15. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 2011; 10:339.
16. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-67.
17. Amaratunga C, Sreng S, Suon S, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 2012; 12:851-8.
18. Tran TH, Nguyen TT, Nguyen HP, et al. In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J 2012; 11:355.
19. Kyaw MP, Nyunt MH, Chit K, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One 2013; 8:e57689.
20. Beshir KB, Sutherland CJ, Sawa P, et al. Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J Infect Dis 2013; 208:2017-24.
21. Borrmann S, Sasi P, Mwai L, et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One 2011; 6:e26005.
22. ANSM. Protocole d'utilisation thérapeutique et De receuil d'informations Malacef (artésunate) 60 mg, poudre et solvant pour solution injectable laboratoire ACE Pharmaceuticals BV // ARTECEF BV, 2013. http://ansm.sante.fr/var/ansm-site/storage/original/application/01d138 a64031bcf9f37fa2737308caa5.pdf. Accessed 18 August 2014.
23. WHO. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000; 94(suppl):1-90.
24. Lopera-Mesa TM, Doumbia S, Chiang S, et al. Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis 2013; 207:1655-63.
25. Perlmann H, Berzins K, Wahlgren M, et al. Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early asexual stages of Plasmodium falciparum. J Exp Med 1984; 159: 1686-704.
26. Maiga AW, Fofana B, Sagara I, et al. No evidence of delayed parasite clearance after oral artesunate treatment of uncomplicated falciparum malaria in Mali. Am J Trop Med Hyg 2012; 87:23-8.
27. Moormann AM. How might infant and paediatric immune responses influence malaria vaccine efficacy?. Parasite Immunol 2009; 31:547-59.
28. Tetteh KK, Osier FH, Salanti A, et al. Analysis of antibodies to newly described Plasmodium falciparum merozoite antigens supports MSPDBL2 as a predicted target of naturally acquired immunity. Infect Immun 2013; 81:3835-42.
29. Richards JS, Arumugam TU, Reiling L, et al. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development. J Immunol 2013; 191:795-809.
30. Chan CL, Renia L, Tan KS. A simplified, sensitive phagocytic assay for malaria cultures facilitated by flow cytometry of differentially-stained cell populations. PLoS One 2012; 7:e38523.
31. Safeukui I, Correas JM, Brousse V, et al. Retention of Plasmodium falciparum ring-infected erythrocytes in the slow, open microcirculation of the human spleen. Blood 2008; 112:2520-8.